Toni Choueiri

New Capabilities

As of June 2026: Leading investigator in adjuvant kidney cancer trials

Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.

Updated Jun 12